Can a heart drug rescue failing kidneys in the ICU?

NCT ID NCT01720030

Completed Disease control Sponsor: VieCuri Medical Centre Source: ClinicalTrials.gov ↗

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial tests whether levosimendan, a drug used to support the heart, can also improve kidney function in adults with acute kidney injury in intensive care. Participants receive either levosimendan or a placebo, and their kidney function is measured daily. The goal is to see if this drug can help kidneys recover faster and reduce complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Levosimendan (Simdax), a drug given intravenously to support heart function and potentially protect the kidneys.
What this could lead to: If effective, levosimendan could offer a new way to help ICU patients recover kidney function during acute kidney injury, potentially reducing the need for dialysis.
What could go wrong: This is a mid-stage trial with a small number of participants, so results may not be conclusive. Levosimendan can affect blood pressure and heart rhythm, which requires careful monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY

Contacts and locations

Locations

VieCuri Medical Center

Venlo, Limburg, NL-5912 BL, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.